Branch of medicine dealing with cancer
POPULARITY
Categories
1,161 episodes with Oncology
397 episodes with Oncology
368 episodes with Oncology
415 episodes with Oncology
334 episodes with Oncology
361 episodes with Oncology
157 episodes with Oncology
118 episodes with Oncology
112 episodes with Oncology
116 episodes with Oncology
116 episodes with Oncology
101 episodes with Oncology
77 episodes with Oncology
118 episodes with Oncology
205 episodes with Oncology
128 episodes with Oncology
77 episodes with Oncology
59 episodes with Oncology
50 episodes with Oncology
43 episodes with Oncology
69 episodes with Oncology
58 episodes with Oncology
53 episodes with Oncology
60 episodes with Oncology
84 episodes with Oncology
88 episodes with Oncology
41 episodes with Oncology
57 episodes with Oncology
41 episodes with Oncology
50 episodes with Oncology
78 episodes with Oncology
50 episodes with Oncology
54 episodes with Oncology
45 episodes with Oncology
37 episodes with Oncology
22 episodes with Oncology
57 episodes with Oncology
63 episodes with Oncology
44 episodes with Oncology
43 episodes with Oncology
28 episodes with Oncology
43 episodes with Oncology
23 episodes with Oncology
36 episodes with Oncology
38 episodes with Oncology
32 episodes with Oncology
76 episodes with Oncology
51 episodes with Oncology
27 episodes with Oncology
39 episodes with Oncology
29 episodes with Oncology
23 episodes with Oncology
17 episodes with Oncology
80 episodes with Oncology
Pancreatic cancer is among the most deadly forms of cancer, and it can be difficult to catch early. But there's some good news: Clinical trials of a new drug called daraxonrasib found that it doubled the survival time of patients with advanced pancreatic cancer. And some oncologists are calling it a game changer—not just for pancreatic cancer, but potentially other forms of cancer too. Ira talks with oncologist Zev Wainberg, who led a clinical trial for the drug. Plus, ALS is a degenerative disease that causes patients to lose their ability to walk, swallow and eventually to breathe. Now, there's a drug for a rare genetic form of ALS that can slow the progression or even reverse some of these symptoms. Ira talks with New York Times health and science reporter Pam Belluck about this new treatment. Guests: Dr. Zev Wainberg is a co-director of UCLA Health's GI Oncology Program. Pam Belluck is a health and science reporter for The New York Times. Other episodes you may enjoy: mRNA Vaccine For Pancreatic Cancer Continues To Show Promise How do clinical trials work, and who can participate? Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, we review the high-yield topic of Ovarian Cancer from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
"There are a huge array of medical dynamics that people endure, and when they leave a lasting impact, a word that we don't use widely enough is the word 'trauma.' There's an entire category of phenomena in the medical arena that are, in fact, traumatic. One way we know that these experiences are traumatic is that we know that huge portions of people who experience things like cancer do indeed develop problems like [post-traumatic stress disorder]," James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about understanding medical trauma in oncology. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 26, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge of medical trauma and its effects on patients with cancer, caregivers, and healthcare professionals. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 315: Processing Grief as an Oncology Nurse Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Episode 276: Support Young Families During a Parent's Cancer Journey Episode 257: Redefining the Bell: The Ethics of Hope for Oncology Nurses and Patients Episode 103: What Oncology Nurses Need to Know to Support Caregivers ONS Voice articles: 'Between Two Kingdoms' Gives Us a Glimpse Into How Patients and Families Experience Malignancy AYA Cancer Survivors Experience Five Times Higher Depression Rates Than Individuals Diagnosed at Older Ages From Stigma to Support: Changing the Cancer Conversation Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD Moral Injury and Trauma in Nursing Trauma-Informed Care Provides Person-Centered Support for Patients During Deep Distress When the Story Ends, Cancer Does Not Win: Reframing Death in Terminal Cancer Care Word Choice Matters When Caring for Patients With Cancer ONS course: ONS Psychosocial Dimensions of Cancer Care™ Clinical Journal of Oncology Nursing articles: Psychosocial Barriers to Care: Recognizing and Responding Through a Trauma-Informed Care Approach Trauma-Informed Care Addressing the Mental and Emotional Needs of Patients With Cancer Oncology Nursing Forum articles: Post-Traumatic Distress and Symptom Experience in Patients With Head and Neck Cancer–Related Tracheostomy and Family Caregivers The Effect of Neuroticism, Fear of Progression, and Self-Efficacy on Post-Traumatic Growth in Patients With Lung Cancer Undergoing Chemotherapy Reclaiming Your Life From Medical Trauma by James C. Jackson To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Many people have a notion about what medical trauma is, but perhaps they lack a definition. I use a definition that is deliberately broad because I think it is better to be inclusive than exclusive. A medical trauma to me is a medical experience or a medical encounter that basically leaves a mark. It leaves an emotional mark, and that mark is significant enough to disrupt your daily life." TS 2:06 "When somebody develops a life-threatening illness—let's say cancer—it's not their problem only. It's very much a family problem. It affects any manner of people. There is literature that says that family members of people with life-threatening conditions often have rates of PTSD that are every bit as high as the patients do. There's also literature that says that if we can identify this issue as a family problem—a family challenge, not just an individual challenge—then very often that patient is going to do better." TS 8:23 "We just need to make space for people to feel however they feel. And we need to emphasize, I think, that in some ways, even though there's no cancer on the scan, cancer casts a long shadow in the lives of people, which is why when patients after cancer see their primary care provider, when they come back for a checkup with oncology, we need to continue this conversation of 'How is your mental health? Are you okay? How's your anxiety? How are you managing?' … We need to be really curious and kind, and we need to query people about how they're doing, even if officially they don't have cancer." TS 16:20 "Trauma-informed care has become a bit of a buzzword in our culture. But when it is engaged correctly, I think it's really important. And I think in a nutshell, what it means is that as providers, we need to recognize that some situations and circumstances are likely to be traumatic, and we need to pivot and engage people differently now that we know that. Specific features of trauma-informed care might be we're really going to value your emotional safety. We're going to emphasize that. We are going to emphasize boundaries. We are going to ask your permission instead of telling you how to do things. We are going to be really attentive to the language we use to engage you because we're aware of there might be things about your situation that are really triggering." TS 28:15 "I think one [misconception] certainly is that it is only afflicting and affecting people who are frail or weak—not very strong. That's emphatically not true. But that's a popular misconception—that if I'm strong enough, if I'm resilient enough, this experience will not be traumatic to me. It's just not true. Medical trauma doesn't just happen in emotionally weak people. Medical trauma can impact people of all sorts." TS 33:42 "The other misconception, I think, is that there is no hope for people in the throes of medical trauma. I'm not advocating 'hopium,' It's a term that was coined, I think, during the pandemic. I don't think that living with medical trauma is all rainbows and unicorns and shiny things. But the truth is, if you get the treatment that you need, you can find a way to thrive with medical trauma even as you're impacted by medical trauma. This, this 'both-and-ness' is really true. You can both be adversely affected and you can even find some beauty in your struggle. Both can be true." TS 34:13 "I wish people understood that there is a name for this phenomenon. We're naming it here today medical trauma. Not everyone who has cancer has medical trauma—not even close—but there are many people who do. And I think many of those people, they don't quite have a name for it. And when I introduce this name for it—trauma—many of them say, 'Oh, my gosh, that makes so much sense. I didn't quite understand why I was struggling so much with this. I didn't quite understand why it casts such a long shadow in my life. I didn't really understand why I was having panic attacks every time I had to get another scan at the oncology office to see if my breast cancer had returned. Now I understand. Now I understand it's because it was trauma.'" TS 35:09
In this episode, we review the high-yield topic of Lung Cancer from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Nearly three in four providers say the pace of oncology innovation is overwhelming. Mark Bishop talks with Advanced Practice Provider (APP) Donna Catamero and emerging APP Becky Moran. New treatments & technologies and the future role of APPs in Oncology. Do you know about The Make it Happen campaign? Listen in on this episode of The Mark Bishop Show. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.
In 2020, Emily Mendenhall drove from Washington, DC to Okoboji, Iowa, a town of 800 that swells to 200,000 every summer, and walked into a pandemic that looked nothing like the one dominating national headlines. Inside gas stations and bars, masks marked you as an outsider. In one stop, a man told her family they would not be served if they kept theirs on. Her 6 year old daughter cried, confused. Mendenhall, a medical anthropologist at Georgetown University, did what she always does. She started asking questions. Over months, she interviewed neighbors, former classmates, and local officials, including her own brother in law who helped lead the local COVID response. The result became Unmasked, a case study in how community identity, economics, and politics shaped public health decisions in real time. That work led directly into her latest book, Invisible Illness: A History, from Hysteria to Long COVID, where she tracks a much older problem. Patients with chronic illness, especially women, often fail to meet medicine's demand for proof. Without a clear diagnosis, they lose access to care, insurance coverage, and legitimacy. Mendenhall argues that long COVID did not create this failure. It exposed it.This conversation centers on how healthcare systems reward certainty and punish complexity. Long COVID clinics send patients to 17 specialists without resolution. Insurance structures require diagnoses that many conditions cannot provide. Medical training still struggles to integrate trauma, mental health, and chronic disease into a coherent model of care.Mendenhall brings lived experience into the conversation. After COVID, she dealt with months of fatigue and escalating anxiety that altered her baseline health. She does not claim the label of long COVID, but she understands how quickly the system becomes harder to navigate once symptoms stop fitting clean categories. The stakes are not theoretical. In the United States, access to healthcare, disability benefits, and treatment still depends on whether a condition can be measured, coded, and reimbursed. For millions living with invisible illness, the burden of proof becomes the illness itself.RELATED LINKSEmily MendenhallInvisible Illness: A History, from Hysteria to Long COVIDScience PoliticsGeorgetown UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
"Cancer" isn't a word anybody wants to hear, either from their doctor or from their vet. For many of us, that word brings with it a host of worries, fears, and uncertainties. It can be hard to know where to look for answers, especially when it comes to our pets- general veterinarians often lack in depth knowledge of cancer, while veterinary oncologists are few and far between. Dr. Erin Malone, a board certified veterinary oncologist, is working to try to change that through her innovative new telehealth service, which aims to provide pet owners with information and guidance about cancer, wherever they are in the country. She joined the show today to talk about canine cancers, their treatments, and where the field of veterinary oncology is headed. For show notes and more, please go to Your Family Dog.
As colorectal cancer rates rise among younger adults, surgeons are increasingly caring for patients with rectal cancer who are pregnant or hoping to preserve future fertility. With more individuals delaying childbearing, balancing effective cancer treatment with fertility preservation and maternal–fetal safety has become an important clinical challenge. This timely topic was recently highlighted by Dr. Sharon Suwanabol during a presentation at the American Society of Colon and Rectal Surgeons annual meeting 2026. In this episode, we explore the intersection of rectal cancer, fertility, and pregnancy through a multidisciplinary, case-based discussion. We review how surgery, chemotherapy, and pelvic radiation can affect fertility and sexual function in both men and women, and why early counseling and referral to reproductive endocrinology specialists are essential. The discussion also emphasizes that evaluation and treatment during pregnancy can often be performed safely, with care individualized based on tumor stage, gestational age, and the patient's goals and values. Hosts and discussants · Dr. Betelhem Yohannes, General surgery resident at the University of Washington · Dr. Griffen Allen, General surgery resident at the University of Washington · Dr. Raga Siddharthan, Assistant Professor of Surgery in the Section of Colorectal Surgery at the University of Washington · Dr. Stacey Cohen, Professor in the Division of Hematology and Oncology at the University of Washington and a gastrointestinal medical oncologist at Fred Hutch Cancer Center, specializing in colorectal and other GI cancers. Learning objectives · Describe the impact of rectal cancer surgery on fertility, sexual function, and future childbearing potential. · Review the effects of chemotherapy and pelvic radiation on reproductive health and fertility preservation. · Discuss available fertility preservation strategies and the importance of early pre-treatment counseling and referral. · Recognize the diagnostic challenges of rectal cancer during pregnancy, including overlapping gastrointestinal symptoms. · Review appropriate staging and workup considerations for suspected rectal cancer in pregnant patients. · Discuss multidisciplinary management strategies for rectal cancer during pregnancy, including individualized treatment sequencing. · Examine ethical and patient-centered considerations when balancing maternal cancer treatment and fetal outcomes. References Siegel RL, Wagle NS, Star J, Kratzer TB, Smith RA, Jemal A. Colorectal cancer statistics, 2026. CA Cancer J Clin. 2026;76(2):e70067. doi:10.3322/caac.70067 [https://pubmed.ncbi.nlm.nih.gov/38240409/] Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11. Obstet Gynecol. 2022;140(2):348-366. doi:10.1097/AOG.0000000000004873 [https://pubmed.ncbi.nlm.nih.gov/35640237/] Stal J, YI SY, Cohen-Cutler S, et al. Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates. Oncologist. 2022;27(7):579-586. doi:10.1093/oncolo/oyac052 [https://pubmed.ncbi.nlm.nih.gov/35708892/] Druvefors E, Myrelid P, Andersson RE, Landerholm K. Female and Male Fertility after Colectomy and Reconstructive Surgery in Inflammatory Bowel Disease: A National Cohort Study from Sweden. J Crohns Colitis. 2023;17(10):1631-1638. doi:10.1093/ecco-jcc/jjad079 [https://pubmed.ncbi.nlm.nih.gov/37341355/] Ito M, Tsukada Y, Watanabe J, et al. Long-term survival and functional outcomes of laparoscopic surgery for clinical stage I ultra-low rectal cancers located within 5 cm of the anal verge: A prospective phase II trial (Ultimate trial). Ann Surg. Published online April 1, 2024. doi:10.1097/SLA.0000000000006290 [https://pubmed.ncbi.nlm.nih.gov/38629555/] Teh WT, Stern C, Chander S, Hickey M. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int. 2014;2014:482968. Johnson GGRJ, Park J, Helewa RM, Goldenberg BA, Nashed M, Hyun E. Total neoadjuvant therapy for rectal cancer: a guide for surgeons. Can J Surg. 2023 Apr 21;66(2):E196-E201. doi: 10.1503/cjs.005822. PMID: 37085291; PMCID: PMC10125160. [https://pubmed.ncbi.nlm.nih.gov/37085291/] Naren G, Guo J, Bai Q, Fan N, Nashun B. Reproductive and developmental toxicities of 5-fluorouracil in model organisms and humans. Expert Rev Mol Med. 2022 Jan 31;24:e9. doi: 10.1017/erm.2022.3. PMID: 35098910; PMCID: PMC9884763. [https://pubmed.ncbi.nlm.nih.gov/35098910/] National Comprehensive Cancer Network. (2026). NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (Version 2.2026). Retrieved from NCCN Guidelines for Rectal Cancer [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1449] Oktay, Kutluk M.D., Ph.D.. Expert Commentary on Fertility Preservation in Colorectal Cancers: Current State and Practical Tips for the Cancer Practitioner. Diseases of the Colon & Rectum 63(6):p 726-727, June 2020. | DOI: 10.1097/DCR.0000000000001688 [https://pubmed.ncbi.nlm.nih.gov/32479532/] Stal J, YI SY, Cohen-Cutler S, et al. Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates. Oncologist. 2022;27(7):579-586. doi:10.1093/oncolo/oyac052 [https://pubmed.ncbi.nlm.nih.gov/35708892/] Gentile G, Ciccarone M. Management of fertility preservation in young female patients with gastrointestinal cancer: A case series and systematic literature review. Curr Probl Cancer. 2025;57:101221. doi:10.1016/j.currproblcancer.2025.101221 [https://pubmed.ncbi.nlm.nih.gov/39598263/] Saif MW. Management of colorectal cancer in pregnancy: a multimodality approach. Clin Colorectal Cancer. 2005;5(4):247-256. doi:10.3816/ccc.2005.n.035 [https://pubmed.ncbi.nlm.nih.gov/16183863/] Rogers JE, Dasari A, Eng C. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. Oncologist. 2016 May;21(5):563-70. doi: 10.1634/theoncologist.2015-0362. Epub 2016 Mar 21. PMID: 27000464; PMCID: PMC4861360. [https://pubmed.ncbi.nlm.nih.gov/27000464/] Jiang Q, Hua H. Fertility in young-onset colorectal patients with cancer: a review. Oncologist. 2024;29(10):e1237-e1245. doi:10.1093/oncolo/oyae141 [https://pubmed.ncbi.nlm.nih.gov/39292850/] Dolmans MM, Hollanders de Ouderaen S, Demylle D, Pirard C. Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment. J Assist Reprod Genet. 2015;32(8):1233-1237. doi:10.1007/s10815-015-0533-z [https://pubmed.ncbi.nlm.nih.gov/26162569/ Moawad NS, Santamaria E, Rhoton-Vlasak A, Lightsey JL. Laparoscopic Ovarian Transposition Before Pelvic Cancer Treatment: Ovarian Function and Fertility Preservation. J Minim Invasive Gynecol. 2017;24(1):28-35. doi:10.1016/j.jmig.2016.08.831 [https://pubmed.ncbi.nlm.nih.gov/27599763/] Fish R. Ovarian transposition in rectal cancer: uncertain benefit at a high price. Colorectal Dis. 2022;24(6):706-707. doi:10.1111/codi.16086 [https://pubmed.ncbi.nlm.nih.gov/35191146/] Ribeiro R, Baiocchi G, Moretti-Marques R, Linhares JC, Costa CN, Pareja R. Uterine transposition for fertility and ovarian function preservation after radiotherapy. Int J Gynecol Cancer. 2023;33(12):1837-1842. Published 2023 Dec 4. doi:10.1136/ijgc-2023-004723 [https://pubmed.ncbi.nlm.nih.gov/38104863/] Haggar F, Pereira G, Preen D, et al. Maternal and neonatal outcomes in pregnancies following colorectal cancer. Surg Endosc. 2013;27(7):2327-2336. doi:10.1007/s00464-012-2774-6 [https://pubmed.ncbi.nlm.nih.gov/23645367/] Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US
In this episode, we review the high-yield topic of Glucagonoma from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Welcome to the Komen Health Equity Revolution series on Real Pink — where patients, advocates, researchers and community partners come together to talk honestly about what's standing in the way of breast health equity, and what we're doing to change it. June is Pride Month — a time to celebrate identity, community and the courage it takes to live authentically. Today's conversation sits right at the heart of that. Because advocating for yourself, knowing your body and refusing to be dismissed, that's not just a health message. That's a love letter to who you are. Our guest today is Shelby Smith. She was 30 years old when she noticed something felt off. No family history of breast cancer. Young, healthy, going about her life as a wife and mom to a 7-year-old daughter. But she trusted herself — and that decision changed everything. Shelby faced a 12-centimeter tumor, a bilateral mastectomy, 16 rounds of chemo and 15 rounds of radiation. She did her own research, built her own notebook, asked her own questions — and came out the other side with a message she wants every young woman to hear: Know your normal. And when something doesn't feel right, advocate for yourself. Key Takeaways: Trust your instincts when something feels off Self-advocacy can change outcomes Being informed helps patients navigate treatment Cancer can affect more than physical health Including loved ones in the journey matters Chapters 00:00 Introduction: Shelby's Breast Cancer Story 02:07 Discovering a Lump and Seeking Answers 04:37 Diagnosis, Testing, and Receiving the News 10:07 Research, Self-Advocacy, and Navigating Treatment 17:33 Identity, Family, and Talking to Her Daughter 24:46 Life After Treatment and Advice for Young Women Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.
In a cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the impact of omidubicel-onlv (Omisirge) on patient outcomes, current research on reducing the risk of graft-vs-host disease (GVHD) among transplantation recipients, and strategies for providing effective prophylaxis during treatment, among other topics.
In a special edition of Oncology On the Go, Chinmay Jani, MD, joined CancerNetwork® in the studio to speak about different research initiatives he is involved with across precision oncology. He discussed ongoing work dedicated to validating and applying artificial intelligence (AI)–based tools in clinical work as well as overcoming immunotherapy resistance among patients with lung cancer.Jani, chief fellow in Hematology and Oncology at University of Miami Sylvester Comprehensive Cancer Center, first detailed findings from a study he presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting evaluating AI decision support in the context of EGFR-mutated non–small cell lung cancer (NSCLC). Although AI systems aligned with expert decision-making in frontline treatment, significant divergence was observed in second-line care, highlighting a need for more rigorous validation and clinical safeguards when integrating AI into oncologic decision-making. Improving documentation and using tools more ethically, Jani said, will also be critical for future applications of AI in field.Jani also spoke about the rapidly evolving thoracic oncology field based on research he and colleagues are leading at the University of Miami. Different investigations are exploring potential advancements in precision medicine, overcoming immunotherapy resistance, and early cancer detection to help elevate outcomes among patients with lung cancer. Looking ahead, Jani emphasized how novel therapeutics like tarlatamab-dlle (Imdelltra) and the incorporation of liquid biopsy may assist with the goal of turning lung cancer into “a chronic disease” where patients can survive not just for a few month or years but for decades.According to Jani, other key concerns in the field include the evolving landscape surrounding adolescent and young adult (AYA) patients, who may require different types of molecular testing and therapeutic needs compared with adult populations. Being able to detect more fusions and alterations that may inform therapeutic strategies via circulating tumor DNA plus circulating tumor RNA or through wider minimal residual disease testing, he said, represents another ongoing goal in terms of precision medicine.ReferenceJani C, Pérez-Granado J, Kalucha A, et al. Evaluating AI decision support in a rapidly evolving therapeutic landscape: EGFR-mutant metastatic NSCLC. J Clin Oncol. 2026;44(suppl 16):1630. doi:10.1200/JCO.2026.44.16_suppl.1630
During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Hosted on Acast. See acast.com/privacy for more information.
The Global Cardio-Oncology Summit is the flagship annual meeting for anyone interested in this field. This year's meeting will be hosted by the team from Virginia Commonwealth University's Pauley Heart Center. Drs. Wendy Bottinor and Fadi Salloum highlight some of the key themes and distinguishing features of this event. Basic science and nursing components will be included. For more information, go to: https://gcos.ic-os.org/
In this episode, we review the high-yield topic of Leiomyoma (Fibroids) from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
"We typically think of the disease progressing for our higher-risk patients because many of them already start with increased blasts or a lot of dysplasia. And they have these chromosomal variants that make them prone to evolving into acute myeloid leukemia (AML). With them, we can anticipate that they are going to progress to AML. And that's what we're trying to prevent. It's kind of like a biologic evolution and not a switch," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about long-term myelodysplastic syndrome (MDS) considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 19, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to management of long-term side effects related to myelodysplastic syndrome and its treatment. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 415: Myelodysplastic Syndrome Treatment Considerations for Oncology Nurses Episode 411: An Overview of Myelodysplastic Syndrome for Oncology Nurses Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 220: Oncologic Emergencies 101: Febrile Neutropenia and Sepsis Clinical Journal of Oncology Nursing articles: Exploring Experiences of Bereaved Caregivers of Older Adult Patients With Acute Myeloid Leukemia Family Caregiver Preparedness: Developing an Educational Intervention for Symptom Management Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Oncology Nursing Forum article: An Integrative Review of Sex Differences in Quality of Life and Symptoms Among Survivors of Hematologic Malignancies ONS book: BMTCN® Certification Review Manual (second edition) ONS course: Psychosocial Dimensions of Cancer Care™ ONS Learning Libraries: Survivorship Learning Library Hematology, Cellular Therapy, and Stem Cell Transplantation Survivorship Care Plan Huddle Card American Association of Colleges of Nursing End-of-Life Nursing Education Consortium (ELNEC) American Cancer Society: Living As a Myelodysplastic Syndrome Survivor American Society of Hematology Aplastic Anemia and MDS International Foundation: MDS Toolkit Blood Cancer United: Myelodysplastic Syndromes Family Caregiver Alliance HealthTree Foundation Inspire: MDS Support and Discussion Community Myelodysplastic Syndromes Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "When our higher-risk patients have disease-related progression, their [malignancy] can transform to AML. And we know this occurs in about one-third of our patients and is one of the most serious late effects. Even in lower-risk disease, we have this worsening marrow failure with or without increasing blast, where [patients] may have just started out with anemia, then they also develop neutropenia and thrombocytopenia. And as those counts worsen, we usually know that their disease is progressing." TS 2:47 "The golden rule is looking at the blood count but also looking at the patient and how they're doing over time. The backbone of MDS monitoring is the complete blood cell count with the differential. What you're looking for is trends over time. How many units of blood are they receiving, what threshold are you going to transfuse them at, and how many units of blood are they getting at a time? ... And then paying attention to the absolute neutrophil count for infection risk. [Another] really important piece of when you look at the differential with patients is seeing if they have any abnormal cell counts. Do they have circulating blasts? Are those monocytes going up? If you start to see blasts circulating or increasing monocytes, then their disease could be changing, even if they have low-risk disease." TS 15:58 "For lower-risk disease, we're paying more attention to their quality of life, how the patient's tolerating therapy, trying to help them stay safe over the long haul, and starting them on iron chelation if it matches that patient and they can have access to those drugs. ... For higher-risk disease, if the patient's goal is to be cured and not to progress to AML, you want to get them to transplant if that's [also] one of their goals. If they do evolve into AML, try and see what treatment matches best for them." TS 22:28 "You want to start early for patients who have febrile neutropenia—that's really important when a patient is an hour or two away from a center where they can get started on antibiotics. So, you have to think outside the box. What can we do to keep them safe? ... I know this group in Alaska that's in our advisory meetings and they try to facilitate transportation to Seattle. That's the closest academic center to them. Collaborating with telemedicine appointments, starting earlier, developing that strong relationship with patients, and contacting them between visits [can help patients living in rural areas]." TS 25:22 "I think the biggest [psychosocial challenge] I see is a lot of unmet anxiety and depression counseling. A lot of times, [patients are] losing their place in their family because they're the ones that need all the help now. Also, the uncertainty that goes along with the diagnosis. There is communication skills counseling, and End-of-Life Nursing Education Consortium (ELNEC) has a lot of training for communication skills and how to really talk to patients. Not that we take the place of a psychologist, but just being able to talk to somebody can go a long way. And if we can get training for that, we can help more patients." TS 31:15
Radiation therapy is a powerful and non-invasive tool in the management of small cell lung cancer (SCLC), but radiation oncologists are not always fully integrated into the care team. In this episode, CANCER BUZZ speaks with Charles B. Simone, II, MD, FASTRO, FACRO, FACR, chief medical officer of the New York Proton Center and radiation oncologist at Memorial Sloan Kettering Cancer Center, about strategies to improve collaboration between radiation and medical oncology. He discusses some of the biggest barriers and greatest rewards of enhancing this partnership and expanding access to radiation therapy for SCLC. Guest: Charles B. Simone, II, MD, FASTRO, FACRO, FACR Research Professor and Chief Medical Officer New York Proton Center Radiation Oncologist Memorial Sloan Kettering Cancer Center New York, NY "While we don't have large, randomized trials really telling us how the modalities should be sequenced, that really should be a discussion and personalized for each patient." —Charles B. Simone, II, MD, FASTRO, FACRO, FACR "After a slow 20 years of limited progress, this last half a decade has seen dramatic progress for small cell, and with that, the multidisciplinary collaboration is even more important." —Charles B. Simone, II, MD, FASTRO, FACRO, FACR Resources: Comprehensive Quality Care for Patients With Small Cell Lung Cancer Small Cell SMASHERS: How Community, Advocacy, and Emerging Science Are Changing the Narrative in Small Cell Lung Cancer
Send us Fan MailThe possible role of deuterium (heavy isotope of hydrogen) in regulating cell division, mitochondrial metabolism & cancer.TOPICS DISCUSSED:Deuterium Basics: Deuterium is twice as massive as regular hydrogen; natural water contains ~150 ppm, with stronger oxygen-deuterium bonds slowing reactions compared to oxygen-hydrogen.Mitochondrial Role: Healthy mitochondria produce deuterium-depleted metabolic water (~110 ppm from fat oxidation vs. ~150 ppm from carbs), helping maintain low cellular D:H ratios.Cell Growth Regulation: Lower deuterium slows cell division in vitro; cells sense small D:H changes, with higher levels (near/above 150 ppm) promoting growth.In Vitro Evidence: DDW (e.g., 25-125 ppm) can reduce proliferation and alters cancer-related gene expression.Animal Models: DDW caused tumor regression in mice with transplanted human cancers and showed possible efficacy in veterinary use for dogs and cats.Human Prostate Cancer: Phase 2 randomized study showed greater Prostate-Specific Antigen (PSA) reduction, tumor shrinkage, and better 1-year survival with DDW plus standard therapy vs. placebo.Dietary Modulation: Ketogenic/high-fat diets lower body deuterium from lipid oxidation.Broader Implications: Potential in neurodegeneration models; larger trials needed for registration as adjunct cancer therapy.ABOUT THE GUEST: Gábor Somlyai, PhD is a molecular biologist who pioneered deuterium depletion studies at the National Institute of Oncology in Hungary. His primary work focuses on the role of deuterium in living organisms and the development of deuterium-depleted water for cancer therapy.Support the showHealth Products by M&M Partners:AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models.OmegaQuant: At-home blood testing to see fatty acid profiles, including omega-3 fatty acids. Use link to see options and support M&M.SiPhox Health: Comprehensive, cost-effective bloodwork from the comfort of home. Use code TRIKOMES for 20% off.KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime)SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code 'nickjikomes' for 20% off.For all the ways you can support my efforts
Eye on the Expert: Eye on ctDNA – What Doctors Are Learning in Uveal Melanoma In this Eye on the Expert webinar, leading experts discuss the growing role of circulating tumor DNA (ctDNA) in uveal melanoma and what this emerging technology may mean for patients and providers. Joining the discussion are: Michael Krainock, Associate Medical Director of Oncology at Natera Dr. Kam Montazeri, Medical Oncologist Dr. Vincent Ma, Medical Oncologist Together, they explore: What ctDNA is and how it is detected through blood testing What doctors are learning about ctDNA in uveal melanoma How ctDNA may be used to monitor disease and treatment response The potential benefits and limitations of this evolving technology Questions patients should ask when considering ctDNA testing As research continues to advance, ctDNA is providing new insights into how cancer can be monitored and understood. This webinar offers an accessible overview of the science, current applications, and future possibilities for patients living with uveal melanoma. Thank you to our sponsors for making this webinar possible: Ideaya Biosciences Delcath Systems Aura Biosciences Castle Biosciences Immunocore Natera Rare Cancer. Resilient Hope. Revolutionary Research.
In this episode, Blood editor Dr. Laura Michaelis interviews Drs. Nigel Russell and Uwe Platzbecker on their articles published in volume 147 issue 10 of Blood. Dr. Russell discuses "CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial" where a large randomized trial demonstrated that DA-GO2 provided greater overall survival as compared to CPX-351, and that further studies should compare DA-GO2 to lower-intensity venetoclax-based regimens. Dr. Platzbecker shares insights from the first prospective study to evaluate the clinical impact of early therapeutic intervention for MRD in "Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial" demonstrating potential therapies for patients to achieve and maintain remission.
Boris Kiselev, MD, explores how cancer diagnosis, treatment, and survivorship can affect patients and the people who care for them. He offers practical guidance for addressing anxiety, grief, trauma, treatment-related mental health symptoms, caregiver stress, fear of recurrence, and the need for coordinated, multidisciplinary support. Interview with Elizabeth Irias, LMFT.Earn CE credit for listening to this episode by joining our low-cost membership for unlimited podcast CE credits for an entire year, with some of the strongest CE approvals in the country (APA, NBCC, ASWB, and more). Learn, grow, and shine with Clearly Clinical Continuing Ed by visiting https://ClearlyClinical.com. Hosted on Acast. See acast.com/privacy for more information.
In this episode, we review the high-yield topic of Basal Cell Carcinoma of the Skin from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Do you know how tumor-agnostic therapies are helping to reshape cancer treatment pathways? Credit available for this activity expires: 6/16/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk?ecd=bdc_podcast_libsyn_mscpedu
At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In oncology, performance is not just about getting patients in the door. It is about getting them to the right specialist, at the right time, with less friction across every handoff. This episode features a presentation from the ROI-Centered Care Summit, a half-day virtual summit produced by Bright Spots Ventures in partnership with TytoCare and the American Telemedicine Association (ATA). In this episode, Yarrow McConnell, MD, FACS, Chief Medical Officer at MultiCare Cancer Institute, shares how MultiCare redesigned oncology pathways to improve access, strengthen coordination, and deliver measurable ROI. You'll hear how MultiCare is: Using AI chart scrubbing to identify cancer diagnoses and concerning imaging findings earlier Deploying nurse navigators to accelerate intake and reduce barriers to care Building APP-staffed workup clinics to move patients more quickly from referral to consult Creating disease teams to improve handoffs and reduce siloed care Standardizing scheduling and authorization workflows, with virtual options built in Improving staging and comorbidity documentation to better reflect complexity and reimbursement Key topics include referral lag, nurse navigation, specialty coordination, scheduling friction, and the connection between operational redesign and financial performance. MultiCare reported a 9% year-over-year increase in operating margin, an increase in likelihood to recommend from 97.86 to 98.41, and a 17% year-over-year increase in teamwork scores. If you are a health system leader, oncology executive, specialty operations leader, or care transformation leader working to improve specialty access and reduce friction across the patient journey, this episode offers a practical look at what it takes to build specialty pathways that perform. Link to Dr. Yarrow McConnel's Presentation: https://www.brightspotsinhealthcare.com/wp-content/uploads/2026/06/ROI-navigation-AIintake-McConnell-2026.pdf Bio: Yarrow McConnell, MD, MSc, FACS, FSSO, is a board-certified surgical oncologist, specializing in the treatment of breast cancer and benign breast disorders. Her expertise includes lumpectomy, mastectomy, sentinel node biopsy, and axillary dissection. She is also highly skilled in oncoplastic techniques to restore breast contour and symmetry following cancer surgery. For patients pursuing reconstruction, Dr. McConnell performs skin and nipple sparing mastectomies in close collaboration with plastic surgeons to provide both immediate and delayed reconstruction options. She also offers flat aesthetic closure for those who choose not to undergo reconstruction. In complex cases involving inflammatory, recurrent, or locally advanced breast cancer, she is experienced in performing modified radical and radical mastectomies. In addition to cancer care, Dr. McConnell treats a variety of benign breast conditions through both in-office and surgical procedures, including cyst aspiration, duct excision, abscess drainage, and steroid injections. She also provides comprehensive breast cancer risk assessments and guidance on genetic testing, enhanced screening, and prevention strategies. Dr. McConnell leads the Breast Program at MultiCare Cancer Institute, overseeing the coordination and advancement of breast care services across the system. Outside of work, Dr. McConnell enjoys gardening, baking, woodworking, and knitting. She can often be found hiking with her husband and dogs or spending time with family and friends. Thank You to Our Episode Partner, TytoCare. TytoCare enables health systems and plans to deliver high-quality remote exams anytime, anywhere. Their FDA-cleared devices and AI-powered diagnostic platform support virtual specialty care, school-based programs, and home health models, reducing unnecessary ED visits and improving patient experience. To learn more, visit tytocare.com. Schedule a Meeting with a Senior Leader at TytoCare: To explore how TytoCare can help your organization expand virtual specialty access and improve care coordination, reach out to jtenzer@brightspotsventures.com to schedule a meeting. About Bright Spots Ventures: Bright Spots Ventures exists to help healthcare organizations accelerate the adoption of what's actually working. Healthcare does not suffer from a lack of innovation. It suffers from slow adoption, fragmented learning, and limited trust between stakeholders. For example, one health plan or provider may solve a major operational or clinical challenge while others spend the next 5–10 years rediscovering the same answer. We close that gap by creating trusted environments where health plans, providers, and innovators can share practical strategies, operational lessons, and scalable models that drive measurable improvement. Through the Bright Spots in Healthcare podcast, leadership councils, executive roundtables, curated events, and strategic advisory work, we help organizations build credibility, strengthen strategic relationships, and accelerate the spread of proven ideas across healthcare.
In this episode, we review the high-yield topic of Pancreatic Cancer from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this sponsored episode of The Top Line, host Stephanie Butler is joined by Sheila Plant, vice president of regulatory affairs at Allucent, to examine how FDA Breakthrough Therapy and RMAT designations can support more strategic oncology development. Although both pathways are intended to speed development, they are not interchangeable. Plant outlines the key distinctions, noting that Breakthrough Therapy requires evidence of substantial improvement over existing treatments, while RMAT centers on early clinical signals that indicate potential to address unmet medical needs. The conversation also explores the strategic choices that determine whether sponsors are ready to pursue these designations, from building a credible data package to designing trials with clinically meaningful endpoints and keeping manufacturing readiness aligned with development timelines. Once a designation is granted, closer collaboration with the FDA can help sponsors navigate development with more dynamic feedback. But as Plant emphasizes, these pathways deliver the greatest value when they are part of a disciplined regulatory strategy. Listen now to learn how sponsors can approach expedited pathways with greater clarity and position oncology programs for meaningful acceleration.See omnystudio.com/listener for privacy information.
“Neuroscience is what oncology was 20 years ago,” says Cristian Massacesi, Chief Medical Officer and Head of Development at Bristol Myers Squibb. Massacesi joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to discuss Bristol Myers’ push into neuroscience, including Alzheimer’s therapies aimed at tau, a protein tied to brain tangles in the disease. They also explore the company’s oncology pipeline, including PD-L1/VEGF bispecifics, next-generation antibody-drug conjugates and advances in multiple myeloma. Massacesi explains how Bristol is balancing internal innovation with external partnerships and why AI could fundamentally change the economics and success rates of drug development.See omnystudio.com/listener for privacy information.
A breast cancer diagnosis may feel like it changes your entire life in an instant, but it doesn't get to define who you are or make all your choices for you. On today's episode of Real Pink, we're joined by Amanda Sangemino, a remarkable young woman whose diagnosis came at an age when cancer was likely the last thing on her mind. What began with a concern that was initially dismissed ultimately led her to trust her instincts, advocate for herself, and make a series of personal decisions about her treatment and future. Throughout the process, she was determined not to let fear and cancer make every decision for her. Today, she'll talk about the choices that she made about fertility, surgical options and maintaining an active lifestyle and why trusting yourself can be one of the most powerful tools you have. Key Takeaways: Mindset can play a powerful role during treatment Trust your instincts and advocate for yourself Maintaining normalcy can be empowering Don't let cancer make every decision for you A strong support system makes a difference Chapters: 00:00 – Amanda's Breast Cancer Story Begins 01:28 – Finding a Lump and Receiving a Misdiagnosis 04:22 – Seeking a Second Opinion and Getting Answers 07:00 – Why Self-Advocacy Matters for Young Women 10:00 – Fertility, Menopause, and Treatment Decisions 14:43 – Choosing Surgery, Staying Active, and Building Support 23:09 – Amanda's Final Advice Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.
In this episode, we review the high-yield topic of Endometrial Carcinoma from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this podcast, experts Hope S. Rugo, MD, FASCO; Fabrice André, MD, PhD; Nadia Harbeck, MD; and Heather McArthur, MD, MPH; discuss updates from the SERENA-6, evERA, PREcoopERA, and TRAK-ER trials of oral selective estrogen receptor degraders (SERDS) in patients with hormone receptor–positive/HER2-negative (HR+/HER2–) early, advanced, and metastatic breast cancer (MBC). These results were presented at European Society for Molecular Oncology (ESMO) Breast 2026.
Cancer is never convenient, and it never arrives when a patient is truly prepared, according to Daniel C. McFarland, DO, who began the most recent episode of Oncology On the Go with this sentiment. When individuals enter the high-stakes, highly coordinated world of oncology, they do so under extreme duress, often presenting the versions of themselves that are most under stress. In this environment, clinical teams frequently encounter behaviors that get unfairly lumped into the vague and pejorative category of the “difficult patient.” What happens when these challenges stem from an underlying personality disorder rather than just temporary situational anxiety? In this episode, McFarland was joined by psycho-oncology expert Kaleena Chilcote, MD, to unpack the inner workings of personality styles and disorders within oncologic science. Together, they explored the Diagnostic and Statistical Manual of Mental Health Disorders (DSM) diagnostic framework, spanning the eccentric, dramatic, and anxious categories. They discussed how these enduring, pervasive traits impact a patient's health care journey. Shifting the conversation away from the stigma of labels, McFarland and Chilcote delivered actionable, real-world advice for oncology teams. They discussed how to utilize objective, descriptive charting; initiate a pause to check your own provider emotions; and build highly consistent, structured boundaries. From managing frequent phone calls to intentionally scheduling short, high-frequency touchpoints, the pair provided a roadmap for turning interpersonal conflict into therapeutic collaboration, proving that underneath the defense mechanisms, every patient has a uniquely valuable strength to connect with. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being a psycho-oncology editorial advisory board member for the journal ONCOLOGY®. Chilcote is director of Psycho-Oncology in the Department of Palliative and Supportive Care at the Taussig Cancer Center, part of the Cleveland Clinic.
In this episode, we review the high-yield topic of Hairy Cell Leukemia (HCL) from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
This week, we take a quick trip to Stockholm, Sweden, where ESTRO (European Society for Radiotherapy and Oncology) took place several weeks ago. A/Prof Steven David digs deep into the latest updates in the breast cancer radiation space, including hyperfractionation of treatment, the utilisation of AI for radiation planning (Archery Trial), and the DBCG RT Natural Trial, which examined whether omitting partial breast irradiation (PBI) after breast-conserving surgery was safe in those over 60 (spoiler: you should still give PBI).For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
In this episode, we review the high-yield topic of Choriocarcinoma from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode, we review the high-yield topic of Soft Tissue Tumors from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
At 20 years old, newly arrived from Puerto Rico and trying to build a future in science, Benjamin Suarez Jimenez found himself sitting in front of two senior faculty members accused of plagiarism. He knew the material. He had done the work. His mistake came from failing to cite class notes during an exam because nobody had told him that was expected. In a matter of minutes, he watched what felt like his entire career flash before him.On this episode of Standard Deviation, host Oliver Bogler examines the hidden architecture of academic science through the experiences of Dr. Benjamin Suarez Jimenez, Assistant Professor at the University of Rochester and a neuroscientist studying PTSD, anxiety, trauma, and spatial cognition through virtual reality and video game environments.Benjamin traces his path from Puerto Rico to the mainland United States, through the NIH, Columbia University, and eventually to leading his own laboratory. Along the way, he encountered a series of barriers that had little to do with scientific ability and everything to do with access to unwritten rules. From academic gatekeeping to grant writing expectations, he learned that success in biomedical research often depends on knowledge that never appears in a textbook.Oliver explores how those invisible obstacles shape careers, influence research funding, and determine who gains access to opportunity. The conversation also examines the Justice, Equity, Diversity, and Inclusion Program at the Life Science Editors Foundation, which pairs scientists from underrepresented backgrounds with experienced scientific editors. Through that mentorship, Benjamin transformed a critical grant proposal into a successful pilot award that helped launch an NIH R01 application.The discussion extends beyond one scientist's experience. Benjamin describes helping a former mentee navigate dissertation roadblocks that threatened her graduation, illustrating how institutional bureaucracy can delay careers and discourage talented researchers. Together, they explore the hidden administrative burden, cultural barriers, and bias that many scientists carry alongside their research, and what happens when someone who receives support turns around and opens the door for others.RELATED LINKSLife Science Editors FoundationBenjamin Suarez Jimenez LabDr. Benjamin Suarez JimenezBenjamin Suarez JimenezFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode, we review the high-yield topic of Platinum Analogs from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Welcome to the Patient from Hell podcast! Live from ASCO 2026, we explore breakthroughs in clinical oncology, cancer research, AI healthcare tools, and targeted therapy for advanced cancer.Samira Daswani, Founder and CEO of Manta Cares and host of The Patient From Hell, sits down with Dr. Doug Blayney, Chief Medical Officer of Manta Cares and former ASCO President, for a candid debrief in between sessions at the 2026 ASCO Annual Meeting in Chicago.With 45,000 oncology professionals in attendance, ASCO is the largest gathering of cancer researchers and clinicians in the world. In this episode, Samira and Dr. Blayney break down what actually mattered: the clinical findings, the shifting treatment landscape, and what the research trends mean for patients navigating cancer today.This episode is for oncologists, cancer researchers, and anyone who wants to understand where the field is heading.Topics covered, with more to come in our next episode:Key clinical findings from ASCO 2026Trends shaping experimental and clinical oncologyWhat high attendance and collaboration signals for the future of cancer researchWhat patients should know coming out of this year's conferenceCHAPTERS:0:00 - ASCO 2026 Annual Meeting Live from Chicago0:27 - Artificial Intelligence (AI) in Oncology & Patient Experience1:19 - Healthcare AI Challenges: Misinformation & Clinician Deskilling2:03 - Pancreatic Cancer Breakthrough: New RAS/KRAS Targeted Therapy2:30 - Lung Cancer Advancements: ALK Mutations & PD-L1 Data3:01 - Breast Cancer Innovation: Oral SERDs & ESR1 Biomarkers3:41 - Next Episode Preview & Wrap UpSubscribe for frequent breakdowns of cancer research, treatment news, patient stories, and guidance and support for people in treatment for cancer. Drop a comment with the topics or trials you want us to cover next!
Send us Fan MailIn this episode of the Life Science Success Podcast my guest is Simran Padam, MD, APMMC, Executive Director of Medical Affairs at Worldwide Clinical Trials. A physician with 17+ years guiding global studies, she shares insights on medical monitoring, complex oncology and hematology programs, and the clinical judgment behind drug development highlighted in her newsletter, The Medical Monitor's Desk.00:00 Show Intro and Guest01:49 Simran Career Journey04:22 Why CRO Variety Matters05:48 What Medical Monitors Do08:04 Protocol vs Reality09:43 Physicians Role Evolving11:14 Better Trial Decisions13:31 Newsletter Behind Scenes16:09 LinkedIn Newsletter Reach17:07 From Science to Execution19:18 Therapeutic Specialization21:20 Collaboration Across Teams23:05 Capabilities for Future25:16 Rapid Fire Inspiration32:44 Where to Connect34:09 Podcast Outro
This week Sara Erger comes on the show talking women's health. She touches on what types of screenings women should be getting, and when the best time is to start. Erger also highlights different types of cancers and HPV risks found in women, and what can be done to prevent this. In addition to this, Erger shines a light on the the rise of colon/rectal cancers in younger age ranges and cancer risks, giving invaluable information to help aid those searching for some answers. Listen To The Local Matters Podcast Today! News Talk 94.1
In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.
Send us Fan MailA cancer diagnosis can change everything in an instant. One conversation. Three words: "You have cancer." Suddenly, patients and families are faced with uncertainty, fear, and countless questions about what comes next.In this episode of MedStar Health DocTalk, host Debra Schindler sits down with medical oncologist and hematologist Dr. Ankit Madan of MedStar Southern Maryland Hospital Center, to discuss the critical first steps after a cancer diagnosis. Dr. Madan explains how patients move from diagnosis to treatment, how cancer is staged, and why building a multidisciplinary care team is essential for the best possible outcomes.The conversation explores the emotional impact of hearing a cancer diagnosis, the importance of patient navigators, social workers, nutritionists, mental health professionals, and the role patients play as active partners in their own care. Dr. Madan also discusses treatment advances, clinical trials, immunotherapy breakthroughs, second opinions, and practical advice for patients and families navigating one of life's most challenging journeys.Whether you or a loved one has recently been diagnosed with cancer, this episode offers guidance, reassurance, and expert insight into what happens after the diagnosis—and how patients can move forward with confidence and support.Topics covered:• Coping with the emotional impact of a cancer diagnosis• Understanding cancer staging and treatment planning• The role of biopsies, CT scans, PET scans, and additional testing• Building a multidisciplinary cancer care team• Patient navigators, social workers, and support services• Shared decision-making and patient autonomy• When to seek a second opinion• Clinical trials and emerging cancer treatments• Immunotherapy and advances in cancer care• Nutrition, exercise, and mental health during treatment• Cancer survivorship and ongoing surveillanceTo learn more about cancer care at MedStar Health, visit MedStarHealth.org/Cancer.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.
In this sponsored episode of The Top Line, experts from Myriad Genetics join host Stephanie Butler to examine how tumor-informed molecular residual disease, or MRD, testing is beginning to redefine what early insight can mean in oncology drug development. As biomarker-driven therapies become more precise, the ability to understand response earlier and more clearly is increasingly being viewed as foundational to smarter development strategy. The discussion looks at how ultrasensitive, tumor-informed MRD assays can help track response over time, potentially surface deeper signals earlier and inform decisions that shape trial design, patient selection and regulatory direction. It also considers why these capabilities may become more important as oncology programs face growing pressure to balance speed, flexibility and evidence generation. Listeners will hear why early diagnostic strategy is increasingly seen as a competitive differentiator, how MRD can help teams make better decisions sooner and why its role in oncology development is expected to continue to evolve and expand.See omnystudio.com/listener for privacy information.
Dr. Sarah Matt trained as a burn surgeon, working in a field where patients arrive with catastrophic injuries and survival depends on speed, skill, and resources. She left the bedside after confronting a limit that medicine does not like to admit. One physician can only see so many people in a day. The system surrounding those patients decides the rest. She moved into health technology, held leadership roles in startups, and built global infrastructure at Oracle to scale care across populations. Then she watched billions of dollars in digital health and AI initiatives stall out when they hit real clinical environments.This episode follows that pivot from surgeon to strategist and back into direct patient care in rural New York, where she now treats uninsured patients, migrant workers, and communities pushed to the margins. The conversation centers on a persistent failure across healthcare systems. Products get built for regulators, executives, and investors instead of the people who use them. The result shows up in failed adoption, broken workflows, prior authorization delays, and rising physician burnout.The discussion cuts through health policy language and lands on lived consequence. The system rewards speed over usability, scale over trust, and compliance over care. Patients absorb the fallout. Physicians carry the liability. The incentives remain intact.RELATED LINKSDr. Sarah MattThe Borderless Healthcare RevolutionThe Clinical RealistJessica FedererSovatoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Better Edge : A Northwestern Medicine podcast for physicians
In this episode of Better Edge, Transplant Hepatologist Laura Lulik, MD moderates a panel discussion about the Northwestern Medicine Liver Transplant Tumor Clinic. The conversation covers advances in imaging, systemic therapies and innovative procedures, as well as the clinic's multidisciplinary approach.The panel includes: • Daniel Borja, MD, transplant surgeon• Aparna Kalyan, MD, medical oncologist • Robert Lewandowski, MD, interventional radiologist• Amira Borhani, MD, abdominal radiologist
Today on National Cancer Survivor's Day, we're joined by a remarkable performer whose strength, vulnerability, and resilience have inspired millions around the world. She has taken the stage as a backup vocalist for numerous top artists and most recently dazzled the crowds on the biggest tour in music history with global superstar Taylor Swift. However, audiences were moved even more deeply when she chose to publicly share something far more personal – her breast cancer journey. After Jeslyn Gorman's diagnosis become known through The Eras Tour docuseries, fans witnessed the emotional reality of navigating cancer while stepping away from a career and community she loves so deeply. From continuing to tour in the early days of diagnosis, to facing treatment side effects and returning to the stage immediately following treatment, her story is one of courage, grace and resilience. Today, Jeslyn opens up about the support she received, what survivorship looks like now and most importantly, shares an empowering message for young women about listening to their bodies, advocating for their health, and never underestimating the importance of early detection. Key Takeaways: Early detection can save lives. You can experience joy and fear at the same time. A strong support system makes a major difference. Recovery is gradual and requires patience. Cancer changes your life, but it doesn't define it. Chapters 00:00 – Jeslyn's Breast Cancer Diagnosis 05:24 – Continuing to Perform After Diagnosis 07:38 – Going Public With Her Cancer Story 13:22 – Breast Health and Self-Advocacy 18:07 – Support From Family, Friends, and the Tour Community 22:17 – Staying Positive During Treatment 25:17 – Chemotherapy and Physical Recovery 31:49 – Hair Loss and Identity Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship. 37:29 – Life After Treatment and Survivorship
In this episode, we review the high-yield topic of Teratoma from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Malignant Bowel Obstruction, VTE and Goals of CareMaster malignant bowel obstruction, cancer-associated thrombosis, and goals-of-care conversations in hospitalized patients with advanced cancer. Learn practical approaches to symptom management, anticoagulation decisions, and navigating high-stakes discussions around prognosis and hospice care. We're joined by Dr. Jensa Morris, @JensaMorrisMD (Yale School of Medicine).Claim free CME for this episode at curbsiders.vcuhealth.org!Show Segments Intro Picks of the Week Case 1: Malignant small bowel obstruction: definitions, initial management, medications, NG tubes, nutrition, and procedural options Case 2: Cancer-associated VTE: choice of anticoagulant, treatment duration, unusual thromboses, and anticoagulation with brain metastases Case 3: Goals of care: prognosis, performance status, palliative care, hospice and end-of-life planningTake Home Points Outro Credits Writer, producer, and show notes: Reaford Blackburn, Jr., MD Infographic, Cover Art: Caroline Coleman, MD Hosts: Monee Amin, MD and Meredith Trubitt, MD Reviewer: Rahul Ganatra, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Jensa Morris, MD Sponsor: Continuing Education CompanyVisit CMEmeeting.org/curbsiders and use promo code Curb30 for 30% off all online courses and webcasts. Sponsor: LocumstoryLocumstory.com is literally just a free, unbiased resource dedicated to educating physicians about locums.Sponsor: Mint MobileTo get your new wireless plan for just 15 bucks a month, go to mintmobile.com/CURB.
© 2020-2026 Ivy Podcast Discovery LLC
